These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases].
    Author: You Y, Xia LH, Zhang C, Liu F, Chen ZC, Zou P.
    Journal: Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3127-9. PubMed ID: 18269872.
    Abstract:
    OBJECTIVE: To investigate the clinical effect of peripheral blood progenitor (PBPC) selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma (NHL) patients. METHODS: Peripheral blood was collected from 5 NHL patients, 3 males and 2 females, aged 29 (14 - 58), t3 with T cell NHL, 1 with diffused large B cell NHL and 1 with genuine histiocytic lymphoma, 2 at the IIA stage and 3 at the IVB stage, and 4 in their first complete remission (CR1) period, and 1 in partial remission (PR2). CD34(+) cells were collected by magnetic-activated cell sorting system, enriched, and re-infused after pretreatment with chemotherapy and granulocyte-colony stimulating factor. Follow-up was conducted for 1 - 44 months. RESULTS: Magnetic-activated cell sorting resulted in 3.3 log depletion of CD34(-) cells and a median yield of CD34(+) selected cells was reinfused with the dose of 2.0 x 10(6)/kg. The median recovery rate of CD34(+) was 52% and purity rate was 86%. The WBC count became > 0.5 x 10(9)/L and the platelet count became > 20 x 10(9)/L at day 12 and day 19 respectively. Both the event-free and overall survival rate were 80.0% (4/5). One-year survival rate and 5-year estimated survival rate were 80% and 75% respectively. CONCLUSION: Brings prompt and stable engraftment, autologous selected PBPC CD34(+) cells transplantation may safely improve the clinical outcome of the patients with NHL.
    [Abstract] [Full Text] [Related] [New Search]